prednisone

P1, N=16, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

Unexplained splenomegaly warrants consideration of primary splenic lymphoma in the differential diagnosis, even without lymphadenopathy or classic B symptoms, particularly when detected during abdominal imaging for hepatosplenic evaluation.Histopathologic and molecular confirmation is essential, as indolent subtypes (e.g. SMZL) and aggressive subtypes (e.g. DLBCL) may present identically but require fundamentally different treatment approaches.PET/CT-guided diagnostic strategy optimises outcomes by enabling accurate staging, identifying the most metabolically active site for biopsy, and informing the need for splenectomy versus direct systemic therapy.

P1, N=12, Not yet recruiting, Astellas Pharma Global Development, Inc.

The patient was managed sequentially with anti-tuberculous therapy (ATT) followed by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, achieving complete remission at six months with 12-month disease-free follow-up. In patients undergoing lymph node biopsy for suspected tuberculosis, it is crucial to thoroughly assess for an underlying lymphoma. Detecting a malignancy in a cervical tuberculous lymph node significantly alters the therapeutic approach and requires coordinated management with medical oncology specialists.

P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2028 --> Sep 2027

P2, N=55, Enrolling by invitation, SWOG Cancer Research Network | Not yet recruiting --> Enrolling by invitation

P2/3, N=102, Active, not recruiting, Tianjin Medical University General Hospital | Recruiting --> Active, not recruiting

P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting

P1/2, N=424, Recruiting, Genmab | Trial completion date: Aug 2029 --> Apr 2028 | Trial primary completion date: Jun 2029 --> Feb 2028

P2, N=90, Active, not recruiting, Rutgers, The State University of New Jersey | Trial completion date: Nov 2026 --> Jun 2027 | Trial primary completion date: Nov 2025 --> Jun 2026

Chemotherapy with l-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisone was initiated; however, neurological symptoms developed after the first cycle. Subsequent cerebrospinal fluid cytology and flow cytometry suggested central nervous system involvement in the lymphoma, and the dog was euthanized owing to disease progression despite the addition of lomustine. To our knowledge, this is the first report of bilateral retrobulbar large B-cell lymphoma with multifocal involvement in a dog. A comprehensive assessment of diagnostic modalities is essential to diagnose extranodal lymphoma and assess extranodal involvement.

P3, N=732, Active, not recruiting, University of Cape Town | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Jun 2024 --> Dec 2025